Tonac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tonac

Property Description
Active ingredient Etodolac
Form Oral Solid (Tablets, Capsules)
Pharmacological class Non-steroidal anti-inflammatory drug (NSAID)
Common use Pain, Inflammation, and Fever Reduction
Origin Synthetic Compound

What Type of Medicine is Tonac and What is it Made of?

Tonac is the brand-name medication containing the active ingredient Etodolac, which is classified as a widely recognized Non-steroidal anti-inflammatory drug (NSAID).

As a synthetic compound, Etodolac is chemically characterized as a pyranocarboxylic acid derivative and belongs to the larger group of propionic acid derivatives. Tonac is manufactured as a single-ingredient product, available in oral solid preparations, specifically tablets and capsules, which are designed for systemic administration. Etodolac provides effective anti-inflammatory and analgesic effects by acting throughout the body, rather than being limited to topical use.


What is the General Purpose of Tonac?

Its general therapeutic purpose, based on its pharmacological class, is to provide simultaneous pain relief, reduce inflammation, and lower fever. The drug achieves this by modulating the body's inflammation mediators, specifically by interfering with the chemical processes that signal pain and produce excessive tissue response. This mechanism is crucial for managing general pain, inflammation, and elevated body temperature. The medicine is effective in reducing swelling and easing discomfort associated with inflammation.


How Does Tonac Compare to Similar Pain Relievers?

Tonac is firmly situated within the established NSAID therapeutic group, which includes many common pain relievers, but it is chemically differentiated by its Etodolac component. While it shares the primary goal of providing systemic pain management and reducing inflammation with other well-known NSAIDs like ibuprofen and naproxen, the specific Etodolac structure distinguishes its pharmacological profile. This comparison clarifies that Tonac is a targeted therapeutic choice within a familiar category of medicines used to alleviate pain and the associated inflammatory response.

Regulatory References

  1. World Health Organization

What side effects are possible with Tonac?

Possible Side Effects and Safety Information

The safety profile of Tonac, which contains the non-steroidal anti-inflammatory drug (NSAID) Etodolac, is structured around adverse reactions affecting multiple physiological systems, as documented in official regulatory classifications. Adverse effects are frequently observed in the Gastrointestinal System and the Nervous System.


Official Frequency and System-Organ Classifications

Adverse reactions classified as Common (occurring in 1% to 10% of users) include dyspepsia, abdominal pain, flatulence, headache, dizziness, and peripheral edema (swelling of extremities). Serious skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are documented as Very Rare.


Serious Adverse Reactions and Safety Constraints

Regulatory documents include mandatory warnings regarding the potential for Serious Cardiovascular Thrombotic Events, including myocardial infarction (MI) and stroke, which can be fatal. There is also an increased risk of serious Gastrointestinal Adverse Events, specifically bleeding, ulceration, and perforation of the stomach or intestines. These serious risks are noted to increase with the duration of use of the medicine.

Safety constraints exist for specific populations and conditions. Use is Contraindicated for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery, in individuals with severe hepatic, renal, or heart failure, and during the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus. Older adults are known to be at a greater risk for serious gastrointestinal complications.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation defines the profile of Etodolac (Tonac) overexposure by its documented acute manifestations and the mandatory emergency response required.

Documented Overdose Manifestations

System Documented Signs and Symptoms
Gastrointestinal Vomiting, Nausea, Stomach pain, Gastrointestinal bleeding/hemorrhage
Central Nervous System Drowsiness (Somnolence), Headache, Tinnitus

Serious systemic outcomes following overexposure may include acute renal failure, metabolic acidosis, gastrointestinal perforation, and severe CNS effects such as convulsions and coma. Regulatory guidance notes that elderly patients are at an increased risk of severe, unwanted effects.

Required Emergency Action

For any suspected overexposure, the official guidance mandates that individuals seek immediate medical attention and contact the Poison Help line or equivalent emergency services. This action is critical because no specific antidote is known for acute Etodolac toxicity. Management is defined as primarily symptomatic and supportive treatment, often requiring hospital monitoring to manage potential life-threatening complications.

Therapeutic Uses of Tonac

Main Uses of Tonac

Tonac is a medication primarily prescribed for the management of pain and inflammation associated with various musculoskeletal and joint conditions. It belongs to the class of medications known as non-steroidal anti-inflammatory drugs (NSAIDs).

Therapeutic Indications

The medication is commonly used to treat symptoms in the following conditions:

  • Osteoarthritis: A degenerative joint disease characterized by the breakdown of joint cartilage and underlying bone.
  • Rheumatoid Arthritis: An autoimmune disorder that primarily affects joints, leading to warm, swollen, and painful areas.
  • Ankylosing Spondylitis: A long-term type of arthritis that affects the spine and large joints.
  • Acute Musculoskeletal Disorders: This includes conditions such as periarthritis (notably frozen shoulder), tendinitis, tenosynovitis, and bursitis.
  • Lower Back Pain: Management of acute episodes of pain in the lumbar region.

Benefits and Mechanism of Action

Tonac works by inhibiting the production of prostaglandins, which are chemicals in the body that signal pain and contribute to inflammation. By reducing these levels, the medication provides several clinical benefits:

  • Pain Reduction: It helps alleviate mild to moderate pain levels associated with chronic inflammatory states.
  • Inflammation Control: It reduces swelling and redness in affected joints or tissues.
  • Improved Mobility: By decreasing pain and stiffness, the medication can help patients maintain better functional movement in their daily activities.
  • Symptomatic Relief in Gout: It is sometimes utilized to manage the pain and inflammation associated with acute gout attacks.

Regulatory References

  1. FDA Verification Portal

Eligibility and Restrictions for Use

Tonac (Etodolac) eligibility is strictly defined by regulatory authorities based on age, physiological status, and pre-existing medical conditions.

Eligibility Status Specific Population Restrictions
Contraindicated Individuals with known NSAID hypersensitivity or aspirin-sensitive asthma. Patients recovering from Coronary Artery Bypass Graft (CABG) surgery. Individuals with severe heart failure or active peptic ulceration.
Pregnancy/Lactation Contraindicated from 30 weeks gestation and later. Use between 20 and 30 weeks is restricted to the lowest effective dose for the shortest duration. Not recommended during lactation as safety is not established.
Age-Group Eligibility Regulatory Status
Adults Use is approved for standard labeled conditions.
Children (Under 6 years) Safety and effectiveness have not been established.
Adolescents (6–16 years) Use is established only for Juvenile Rheumatoid Arthritis (extended-release form).
Older Adults (65+) Use requires caution due to increased risk of serious gastrointestinal events.

Use is not recommended in patients with severe renal impairment. The medicine should be used with caution in patients with severe hepatic failure, uncontrolled hypertension, or established ischaemic heart disease. Eligibility is subject to these strict regulatory exclusions, which delineate approved and non-approved populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Tonac (Etodolac) is defined by its potential for both pharmacodynamic and pharmacokinetic interactions, as documented in official regulatory labeling. Co-administration restrictions exist due to the risk of compounding adverse effects or altering drug exposure.

Documented Pharmacodynamic Interactions

Interacting Product Category Official Interaction Statement
Other NSAIDs (including Aspirin) Increased risk of serious gastrointestinal events, including bleeding and ulceration.
Anticoagulants (e.g., Warfarin) Increased risk of serious bleeding events due to a synergistic effect.
Diuretics / ACE Inhibitors Attenuation of antihypertensive and diuretic effects; increased risk of renal insufficiency.

Documented Pharmacokinetic Interactions

Interacting Product Category Official Interaction Statement
CYP2C9 Inhibitors (e.g., Fluconazole) Pharmacokinetic interaction resulting in a significant increase in Etodolac plasma exposure.
Methotrexate / Lithium Reduction of renal clearance of the co-administered drug, leading to elevated serum concentrations and potential toxicity.
Phenylbutazone Causes a substantial increase (approximately 80%) in the free fraction of Etodolac in plasma.

Substance and Condition-Specific Restrictions

Alcohol consumption is documented to increase the risk of gastrointestinal irritation and bleeding. Administration with Food affects absorption by reducing the peak concentration (Cmax) but does not change the total exposure (AUC).

Regulatory documents emphasize that elderly patients face a greater risk for serious interaction outcomes, particularly those involving renal and gastrointestinal toxicities, when co-administered with interacting agents.

Mechanism of Action

How Tonac Works

Tonac’s mechanism of action is defined by the preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme. This enzyme is primarily activated during tissue injury, making it the core molecular target. By engaging in competitive, reversible inhibition of the COX-2 enzyme, the active component, Etodolac, blocks the first molecular step in the Arachidonic Acid Cascade, thereby suppressing the synthesis of pro-inflammatory prostaglandins.

This molecular alteration initiates a dual physiological cascade. Peripherally, the reduction of prostaglandins alters the chemical sensitization threshold of peripheral nociceptors (pain-sensing nerve endings). This results in the decreased amplification of pain signals and a physiological reduction in localized vasodilation and edema, thereby altering the characteristics of the inflammatory response. Centrally, the mechanism involves activity within the hypothalamus, where reduced prostaglandin synthesis causes the thermoregulatory set-point to revert toward the physiological baseline, initiating processes like peripheral vasodilation for heat dissipation.

Dosage and Administration Information

How to Use Tonac

Tonac is an orally administered medication containing Etodolac, intended for systemic application. It is manufactured in two main forms that define the administration pattern: Immediate-Release (IR) capsules and tablets, and Extended-Release (ER) tablets. The general principle across all regimens is the utilization of the lowest effective dosage.


Dosing and Frequency

Standard adult dosing is dependent on the therapeutic context and formulation type:

Context Form Dose Range (Daily) Frequency Max Daily Dose
Acute Pain IR 200 mg to 400 mg per dose 3 to 4 times daily (every 6–8 hrs) 1000 mg
Chronic Symptoms ER 400 mg to 1000 mg Once daily 1200 mg

Administration Conditions and Special Rules

Tonac tablets and capsules may be taken with or after food, or with a full glass of water, to minimize potential gastrointestinal effects. The IR form may be taken 30 minutes before or 2 hours after meals if a faster onset is required.

Critical Instruction for Extended-Release Tablets

The Extended-Release tablets must be swallowed whole. They are designed to release the medication slowly over time, and they must not be crushed, broken, or chewed under any circumstance.


Population-Specific Usage

No initial dose adjustment is generally required for older adults (65 years and older) or for patients with mild to moderate renal or hepatic impairment. For pediatric patients (6–16 years), only the ER form is used, administered as a weight-based regimen.

Recent Clinical Evidence

Research evidence / Overview of Studies for Tonac

Evidence for Symptomatic Relief of Acute Pain

Research exploring the use of Tonac (Etodolac) has focused significantly on short-term Randomized Controlled Trials (RCTs). These trials are used in studies examining patient-reported experiences related to physical discomfort. Studies monitored outcomes related to symptom intensity or variability, typically comparing how patient-reported pain scores evolved in groups receiving Etodolac against those receiving an inactive placebo or other known anti-inflammatory agents. This research has examined how symptoms changed over defined time intervals.

The findings describe patterns observed in the studies related to temporary discomfort, such as following certain medical or dental procedures. Research highlights changes measured during the study period, with studies reporting how symptoms evolved in the observed populations, and findings indicate patterns related to the perceived discomfort over short follow-up periods. Data indicate patterns related to temporary changes, but there is limited information for long-term outcomes of this use.

Evidence for Managing Inflammation and Musculoskeletal Symptoms

Tonac was evaluated in controlled trials and longer-term observational studies for conditions characterized by fluctuating or episodic manifestations involving periods of heightened symptoms, particularly those linked to inflammatory or irritative states. Studies explored outcomes linked to inflammatory states, and research examined clinical metrics such as joint tenderness, swelling, and patient-reported changes in mobility and stiffness. These trials are relevant in evidence describing how symptoms are measured in conditions marked by functional limitations.

Studies monitored outcomes reflecting daily functioning or activity level, and research also examined changes using validated functional status scales. Data collection primarily focused on the short-to-medium-term symptomatic response to inflammation. Information regarding the effect on the underlying progression of chronic musculoskeletal or inflammatory conditions is not typically a primary outcome in the clinical trials for this medicine.

The Landscape of Long-Term Studies and Follow-Up Data

Studies conducted during periods of increased symptom activity are generally short-to-medium-term, with typical follow-up durations lasting up to a few months for core clinical evaluations. Research has explored short-term symptom changes, but long-term outcomes are not fully established by the same high-certainty RCTs that explore acute change. This evidence contributes to understanding symptom patterns over time, but the long-term status is not fully established, as data for long-term outcomes rely less on controlled study conditions. The findings describe group patterns, not personal outcomes.

Research in Special Populations

Research has explored the use in specific cohorts, such as older adults (aged 65 and above), with studies conducted during periods of increased symptom activity in this group. However, sample sizes were modest for dedicated subgroup analyses, meaning results apply only to the populations studied, and data for certain groups remain insufficient. For patients with pre-existing or co-existing health conditions (comorbidities), findings were mixed or limited in core clinical trials. Subgroup findings are uncertain.

What Remains Uncertain in the Research Landscape

Follow-up durations were limited in key trials, meaning there is limited information for long-term outcomes, and the long-term status remains to be fully established over years. Comparative evidence is lacking for direct, head-to-head evaluation against all other pain relievers in the same class. Additionally, data for certain groups remain insufficient, particularly for those with medically complex situations.

Key Studies & References

  1. Etodolac: FDA Verification Portal/Summary of Therapeutic Indications
  2. World Health Organization Model List of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Tonac (FAQ)


Q: How long does it typically take to notice the expected effects of Tonac?

A: Official information indicates that for certain chronic conditions, a therapeutic response is often observed within two weeks of starting therapy, although some people may notice effects sooner. Regulatory documents describe the intended effect as symptomatic relief, and the time this takes can vary depending on the condition and individual response.


Q: Can Tonac cause weight gain or weight loss?

A: Regulatory documents list abnormal weight and rapid weight gain among the adverse events observed in postmarketing reports. Rapid weight gain is often related to fluid retention or edema (swelling), which is a possible side effect of NSAIDs like Tonac. This information is based on official safety documents, which reference the potential for fluid retention.


Q: Is it normal to feel a little dizzy when first starting Tonac?

A: Yes, feeling dizzy is classified as a common side effect in the official product information for Tonac, meaning it has been reported to occur in 1% to 10% of users in clinical trials. Official documents describe this as one of the transient, common effects. As with any medication that may cause dizziness, official information notes that performance of activities requiring alertness may be affected.


Q: Are the side effects of Tonac permanent?

A: Many common side effects, such as headache or dizziness, are generally temporary and often lessen as the body adjusts to the medication. However, official warnings describe the potential for rare, serious events (such as severe gastrointestinal, kidney, or liver problems) which can potentially cause long-term damage and may lead to the medication being discontinued under medical guidance.


Q: Can taking Tonac affect my sleep patterns?

A: Official adverse reaction reports for the nervous system have included both insomnia (difficulty sleeping) and somnolence (drowsiness) in clinical trial reports. These events are reported in official documents as part of the known adverse reaction profile.


Q: Is Tonac known to cause 'brain fog' or difficulty concentrating?

A: Official adverse reaction reports for the central nervous system have noted effects like confusion, nervousness, and anxiety. These events relate to cognitive changes some individuals may experience while using the medicine.


Q: Does Tonac require any specific monitoring or blood tests while I'm using it?

A: For individuals on long-term treatment, regulatory documents advise that blood tests be performed to check the patient's red blood cell count (hemoglobin or hematocrit). Routine monitoring for signs of renal (kidney) and hepatic (liver) impairment is also part of official safety precautions.


Q: Is it okay to take Tonac if I have a history of kidney problems?

A: Use of the medicine is not recommended in patients with a current diagnosis of severe renal impairment. Official documentation states that for patients with any history of kidney issues, close monitoring for signs of renal failure is necessary during use, as NSAIDs are known to potentially affect kidney function.


Q: Can Tonac interact with herbal remedies or vitamins?

A: While the specific interactions with every herbal remedy are not listed, official regulatory documents explicitly advise patients to inform their healthcare provider about all other medications, vitamins, and herbs they are using. This is because there is a potential for undocumented interactions that could affect drug exposure or safety.


Q: Is there a maximum time a person is recommended to take Tonac?

A: Tonac is officially approved for both acute and long-term use for specific medical conditions. However, the risk of serious side effects, including serious cardiovascular and gastrointestinal events, is stated to increase with the duration of use of the medicine.


Q: Does Tonac interact with common cold or flu medications?

A: Many over-the-counter cold and flu medications contain other NSAIDs or aspirin. Regulatory documents advise that co-administration with other NSAIDs is not generally recommended because it increases the risk of serious gastrointestinal complications, such as bleeding and ulceration.


Q: Is it mandatory to take Tonac with food?

A: No, it is not mandatory. Regulatory documents state that Tonac tablets and capsules may be taken with or after food or with a full glass of water. Taking it with food is typically suggested as a way to help minimize potential gastrointestinal discomfort.


Q: What percentage of users experience the most common side effects of Tonac?

A: Adverse reactions that are classified as Common in regulatory documents—such as dyspepsia (indigestion), headache, and dizziness—are reported to occur in 1% to 10% of patients participating in clinical trials. The most common side effects have the highest reported incidence rate within this range.


Q: Can Tonac affect my ability to drive or operate machinery?

A: Official safety information indicates that the medication is associated with common adverse effects such as dizziness and somnolence (drowsiness). These effects can impair a person's judgment or reaction time, which may affect the ability to safely drive or operate complex machinery.


Q: Is Tonac usually taken for a short period or long-term?

A: Official regulatory documents indicate that Tonac is approved for both treatment paradigms. It is used for acute (short-term) pain management and for long-term use in treating chronic conditions like osteoarthritis and rheumatoid arthritis, depending on the therapeutic need.


Q: Are there any signs that Tonac might not be working for me?

A: For chronic inflammatory conditions, official documents note that if a therapeutic response has not been observed by two weeks of therapy, the clinical decision to review or adjust the dosage or treatment plan may be necessary.


Q: Is the tiredness I feel from Tonac a temporary side effect?

A: Tiredness/fatigue and asthenia (lack of strength) are noted in adverse reaction reports. As with many common side effects of medicine, these are often temporary and tend to lessen or resolve as the body becomes used to the medication over time.


Q: Is Tonac a drug that is easy to quit using if the condition improves?

A: Regulatory information indicates that discontinuation of NSAIDs does not typically require a tapering schedule. However, changes to treatment, including discontinuation, are typically made with professional guidance.


Q: Why is Tonac sometimes used alongside another medication?

A: Official safety warnings indicate that when the medicine is used with other specific drugs, such as certain blood pressure medications, close monitoring is required to assure the other drug remains effective. Additionally, it can be administered alongside antacids to help reduce potential gastrointestinal discomfort associated with NSAIDs.


Q: Can Tonac cause changes in vision or eye problems?

A: Adverse events reported in official documentation have included specific vision-related issues such as blurred vision and optic neuritis (inflammation of the optic nerve). Official documents state that individuals should monitor for and discuss any vision changes while using the medication.


Q: Can Tonac cause skin rashes or increased sensitivity to the sun?

A: Yes, common adverse reactions listed in official documents include rash and pruritus (itching). Furthermore, regulatory documents warn that Tonac belongs to a class of drugs that can cause severe skin reactions, such as Stevens-Johnson Syndrome (SJS), though these are rare.

How should Tonac be stored and disposed of?

Tonac (Etodolac) must be stored at controlled room temperature, typically defined by regulatory agencies as between 15 C and 30 C. It is mandatory to keep from freezing and to avoid storing the medication in areas of excess heat or moisture.

The medication must be dispensed and kept in a well-closed container and should remain tightly closed in the original packaging. This is required to protect from moisture and maintain product stability. For safety, the product must be stored out of the reach of children.

Expired or unused Tonac must not be kept. Regulatory instructions require consumers to consult a healthcare professional or pharmacist on the proper disposal of the unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tonac found in:

A-Z Index: